---
title: "Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286821092.md"
description: "Inovio Pharmaceuticals Inc. (INO) shares fell 6.15% to $1.22 on Monday, marking the second consecutive day of losses. The stock is now 59.05% below its 52-week high of $2.98. In contrast, competitors like Johnson & Johnson and Pfizer remained stable, while the overall market showed mixed results with the Dow up 0.32% and NASDAQ down 0.51%. Trading volume was 5.3 million, surpassing the 50-day average of 2.7 million."
datetime: "2026-05-18T21:24:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286821092.md)
  - [en](https://longbridge.com/en/news/286821092.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286821092.md)
---

# Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Inovio Pharmaceuticals Inc. (INO) slid 6.15% to $1.22 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.32% to 49,686.12 and the NASDAQ Composite Index falling 0.51% to 26,090.73.

This was the stock's second consecutive day of losses.

Inovio Pharmaceuticals Inc. closed 59.05% below its 52-week high of $2.98, which the company achieved on September 9th.

The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson (JNJ) rose 0.97% to $228.92, Statera Biopharma Inc. (STAB) remained unchanged, and Pfizer Inc. (PFE) remained unchanged.

Trading volume (5.3 M) eclipsed its 50-day average volume of 2.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 18, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-18-26 1724ET

### Related Stocks

- [INO.US](https://longbridge.com/en/quote/INO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)
- [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)